Psychedelic Business News Spotlight: January 15, 2021

Psychedelic Business News Spotlight: January 15, 2021

This week in psychedelic business news, IPOs, employee stock options, mergers, research, and more.

Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)

In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth. Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0. This, however, could not be further from the truth. To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks. To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel. Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months: MindMed Stock MMED/MMEDF): 864% Numinuss Wellness (NUMI): 555% Revive Therapeutics (RVV): 166% Compass Pathways (CMPS): 88% The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains. #psychedelicstocks #shroomstocks #mindmedstock https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0 Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Is Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)

In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin. To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things: What problem is Compass Pathways trying to solve? CMPS’ clinical trial, treating depression with psilocybin The founders and leaders of Compass Pathways Compass’ Financials Is CMPS stock a good investment for a retail investor? As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity. Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021? Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. Resources: https://compasspathways.com/ https://www.webmd.com/depression/understanding-depression-basics#1 https://www.psychiatry.org/patients-families/depression/what-is-depression https://www.nimh.nih.gov/health/statistics/major-depression.shtml https://www.webmd.com/depression/guide/depression-treatment-options#1 https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1 https://www.beckleyfoundation.org/psilocybin-for-depression-2 https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav https://psychedelicreview.com/person/ekaterina-malievskaia/ https://compasspathways.com/team-member/george-goldsmith/ https://compasspathways.com/team-member/lars-christian-wilde/ https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html https://www.treehugger.com/facts-about-magic-mushrooms-4868810 https://psychedelicreview.com/person/ekaterina-malievskaia/ #CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor
Psychedelic Business News

Psychedelic Business News Spotlight: January 08, 2021

This week in psychedelic business news, Mydecine, Neon Mind, Ehave, and more.
NeonMind Takes Psilocybin Therapy Public

NeonMind Takes Psilocybin Therapy Public

NeonMind is the latest psychedelic company to go public. It's the first to launch on the Canadian Stock Exchange in 2021.
5 Psychedelic Apps

These 5 Apps Are Made for Taking Psychedelics

,
Taking psychedelics? There's an app for that. These companies are leading the way with trip guides, support, and more.

MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀

In this video, I discuss how MindMed's LSD Neutralizer is GENIUS: MindMed Stock's Massive Opportunity (MMED/MMEDF. 🔥 MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry. MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed's potential uplisiting on to the Nasdaq. Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMedStock #MindMed #MMED #MMEDF
Psychedelic Trend Predictions 2021

7 Psychedelic Trend Predictions for 2021

The momentum for psychedelics is snowballing, and 2021 is expected to be an even bigger and better year for the industry.

Why I’m More Excited About MindMed’s 18-MC than its LSD treatments

Happy Holidays guys! I 🎄🙃 In this episode we'll cover the many reasons why I'm more excited about MindMed's 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed's plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021. Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. #MindMed #MMED #MMEDF #mindmedstock

MindMed ‘s Plan to END the Opioid Epidemic (How MMED / MMEDF Could Make Billions)

It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it's ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors' prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out! Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! Instagram: @psychedelicinvestor Facebook: @thepsychedelicinvestor Music: www.bensound.com DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. Resources https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm https://www.ncbi.nlm.nih.gov/books/NBK541390/#:~:text=Morethan2millionpeople,diseasestraumaandsuicide. https://www.hhs.gov/opioids/about-the-epidemic/opioid-crisis-statistics/index.html#:~:text=In2018anestimated10.3,and808000peopleusedheroin.&text=Appropriateprescribingofopioidsis,andsafetyofMedicarebeneficiaries. https://www.ccsa.ca/opioids#:~:text=Canadaisinthemidst,publichealthandsafetyconcern. https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.17477 https://www.publichealthontario.ca/-/media/documents/o/2020/opioid-mortality-covid-surveillance-report.pdf?la=en https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery https://preprod.drugfree.org/article/relapse-overdose/ https://mindmed.co/psychedelic-inspired/#scroll_section-1 https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/Treating+drug+dependence+with+the+aid+of+ibogaine_a+retrospective+study.pdf https://americanaddictioncenters.org/meth-treatment/success-rate-for-ibogaine https://thethirdwave.co/psychedelics/ibogaine/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382526/#:~:text=Theantiaddictiondrugibogainecertainlyaffectstheheartand,ibogaine'spotentiallylifethreateningcardiotoxicity. https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf https://www.ibogainealliance.org/18-mc/ https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf #MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks